173838-41-0

Basic information

• Product Name: 1H-Imidazole-1-butanamine, 4-phenyl-
• CAS NO: 173838-41-0
• Molecular Formula: C13H17N3
• Molecular Weight: 215.298
• Mol File: 173838-41-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1H-Imidazole-1-butanamine, 4-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Imidazole-1-butanamine, 4-phenyl-(173838-41-0)
• EPA Substance Registry System: 1H-Imidazole-1-butanamine, 4-phenyl-(173838-41-0)

Safety Data

• Hazardous Substances Data: 173838-41-0(Hazardous Substances Data)

Usage

Structure

Imidazole derivative with a butylamine side chain and a phenyl group attached to the imidazole ring

Usage

Intermediate in the synthesis of pharmaceuticals and other organic compounds

Potential applications

Development of new drugs due to structural versatility and ability to interact with biological systems

Industrial applications

Building block in the creation of new materials and compounds

Upstream product

• 670-95-1 4-Phenylimidazole 
• 173838-42-1 2-[4-(4-phenyl-imidazol-1-yl)-butyl]-isoindole-1,3-dione 

Downstream Products

• 484672-03-9 benzoic acid 4-dimethylamino-2-{4-ethyl-11-methoxy-7,9,11,13,15-pentamethyl-2,6,8,14-tetraoxo-1-[4-(4-phenyl-imidazol-1-yl)-butyl]-tetradecahydro-3,5-dioxa-1-aza-cyclopentacyclotetradecen-10-yloxy}-6-methyl-tetrahydro-pyran-3-yl ester 
• 1355008-62-6 C₆₀H₇₉N₅O₁₂ 
• 484672-93-7 C₆₆H₈₇F₃N₄O₁₅ 

Relevant articles and documents

Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens

In the search for new ketolides with improved activities against erythromycin-resistant S. pneumoniae and H. influenzae we synthesized a new 11,12 carbamate ketolide substituted by an imidazo-pyridyl side chain: HMR 3647. This compound demonstrated a potent activity against erythromycin susceptible and resistant pathogens, including penicillin G/erythromycin A-resistant S. pneumoniae and H. influenzae. In vivo, HMR 3647 displayed good pharmacokinetic parameters (Cmax = 2.9 μg/ml, bioavailability = 49%, AUC0-8 = 17.2 μg.h/l, t( 1/2 )= lh) and was shown to have a high therapeutic efficacy in mice infected by various respiratory pathogens, including multi-resistant S. pneumoniae and Gram negative bacteria such as H. influenzae. HMR 3647 appears to be a very promising agent for the treatment of respiratory infections and is currently in clinical trials.